Fiala

Peptide library › Cancer & imaging

Motixafortide

Also known as Aphexda

FDA-approved drugCancer & imaging

Injection that releases stem cells from the bone marrow so they can be collected before a transplant for multiple myeloma.

What people use it for

What Motixafortide does in the body

Blocks CXCR4, the receptor that anchors stem cells in the bone marrow, so they move into the blood where they can be collected. It's used with filgrastim.

Strength of evidence

Strong: the Phase 3 GENESIS trial collected enough stem cells in more patients with fewer collection sessions.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved in 2023. Given in specialist centres with premedication.

How it's taken

Route: Injection under the skin before stem cell collection

How long it lasts (half-life): About 2 hours

Storage

Stored and prepared by the pharmacy or clinic, following the product label.

Keep track of Motixafortide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Motixafortide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Cancer & imaging